We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Instem Plc | INS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 830.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 830.00 | 830.00 |
| Top Posts |
|---|
Posted at 13/10/2023 11:36 by p1nkfish Agreed tt but too many unknowns and the only things I can know is where my stop would sit and the potential risk vs reward.Lion will also pay a price if they allow this to be sold at what they think is too cheap. Future Lion investors will be more sceptical of Lions assessment of a company future value potential. |
Posted at 15/5/2023 21:28 by elrico Adjusted EBITDA loss and net cash outflow resulting from its buy-and-build acquisitions have had an impact on 2022. Investors should focus on what INS has built with accretive acquisitions. |
Posted at 31/10/2019 19:07 by sharesoc Instem present at our next Manchester seminar on the 19th November which may be of interest to potential investors and current shareholders. More details and registration here: |
Posted at 25/10/2019 13:23 by tomps2 Here's the Instem investor presentation by Phil Reason, CEO. Given at the piworld-Progressive Equity Research event in September. Phil was over for the H1 19 results, (normally he's in the US).A very comprehensive overview of the different parts of the business, and a positive outlook. |
Posted at 12/4/2019 14:11 by mw8156 Thanks for that insight, P1NK, hadn't occurred to me, but they did say something about wanting to get more into clinical trial data submission software at their small investor event, seem to recall,rather alarmed that their NTAV is negative and they don't pay any divi so high-risk to that extent especially if a placing is in the offing. |
Posted at 06/2/2019 21:53 by mw8156 would have bought more were it not for the possibility of a transformational acquisition and placing in which small investors might have been excluded. |
Posted at 23/1/2018 16:12 by p1nkfish Video on proactive investor, Phil Reason. |
Posted at 28/4/2017 22:01 by p1nkfish I do enjoy a quiet pbb, especially when a large investor repeatedly ups their holding in an otherwise unloved company with small float. |
Posted at 25/8/2016 10:56 by proactivest Video interview with Phil ReasonInstem PLC (LON:INS) chief executive Phil Reason tells Proactive Investors that the company wants to “dominate&rdqu “We think we can do as we do in many other areas of our business and be a market leader in a particular niche,” Reason says. “We have some particular areas where we think we can dominate some of those niches.” Reason adds that the biotech industry, the company’s main market, has been “buoyant&rdquo “The contact research organisations that make up a lot of our client base today, their facilities are generally full as they conduct probably the largest numbers of studies they’ve ever enjoyed.” |
Posted at 13/10/2010 07:54 by andrbea COMMENCEMENT OF DEALING IN SHARESInstem Life Science Systems plc (AIM:INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to announce that dealings will commence today in its Ordinary Shares following its admission to AIM, under the ticker INS. Instem has raised £9.15 million (prior to expenses) through a placing by Brewin Dolphin of 5,228,376 new Ordinary Shares at the placing price of 175p per share. Following the placing, there will be 11,714,286 Ordinary Shares in issue, giving Instem a market capitalisation of £20.50 million at the placing price. The percentage of Ordinary Shares in public hands on Admission will be approximately 45 per cent. Based in Staffordshire, Instem is the leading provider of Early Development Safety Assessment software, providing its services to over 80 customers, including seven of the top ten global pharmaceutical and biotech companies. The Company has in place a reputable and established business, primarily in North America, Europe and the UK, and expects to grow organically, and where appropriate, acquisitively to accelerate its growth trajectory. General market drivers such as increased R&D productivity requirements, increasing regulatory pressure, growing Far Eastern markets and the ongoing trend to outsource are expected to drive increased demand for Instem's solutions. Phil Reason, CEO of Instem Life Science Systems plc, commented, "We have been delighted with the response from investors and believe AIM will provide us with an excellent platform as we seek to further our market leading position through both organic and acquisitive growth." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
